BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 36449664)

  • 1. Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases.
    Wijetunga NA; Goglia AG; Weinhold N; Berger MF; Cislo M; Higginson DS; Chabot K; Osman AM; Schaff L; Pentsova E; Miller AM; Powell SN; Boire A; Yang JT
    Clin Cancer Res; 2023 Feb; 29(4):775-783. PubMed ID: 36449664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative cerebrospinal fluid circulating tumor cells are a potential biomarker of response for proton craniospinal irradiation for leptomeningeal metastasis.
    Wijetunga NA; Boire A; Young RJ; Yamada Y; Wolden S; Yu H; Kris M; Seidman A; Betof-Warner A; Diaz M; Reiner A; Malani R; Pentsova E; Yang JT
    Neurooncol Adv; 2021; 3(1):vdab181. PubMed ID: 34993483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized Phase II Trial of Proton Craniospinal Irradiation Versus Photon Involved-Field Radiotherapy for Patients With Solid Tumor Leptomeningeal Metastasis.
    Yang JT; Wijetunga NA; Pentsova E; Wolden S; Young RJ; Correa D; Zhang Z; Zheng J; Steckler A; Bucwinska W; Bernstein A; Betof Warner A; Yu H; Kris MG; Seidman AD; Wilcox JA; Malani R; Lin A; DeAngelis LM; Lee NY; Powell SN; Boire A
    J Clin Oncol; 2022 Nov; 40(33):3858-3867. PubMed ID: 35802849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid circulating tumour DNA genotyping and survival analysis in lung adenocarcinoma with leptomeningeal metastases.
    Bai K; Chen X; Qi X; Zhang Y; Zou Y; Li J; Yu L; Li Y; Jiang J; Yang Y; Liu Y; Feng S; Bu H
    J Neurooncol; 2023 Oct; 165(1):149-160. PubMed ID: 37897649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic monitoring of cerebrospinal fluid circulating tumor DNA to identify unique genetic profiles of brain metastatic tumors and better predict intracranial tumor responses in non-small cell lung cancer patients with brain metastases: a prospective cohort study (GASTO 1028).
    Li M; Chen J; Zhang B; Yu J; Wang N; Li D; Shao Y; Zhu D; Liang C; Ma Y; Ou Q; Hou X; Chen L
    BMC Med; 2022 Nov; 20(1):398. PubMed ID: 36372873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The joint detection of CEA and ctDNA in cerebrospinal fluid: an auxiliary tool for the diagnosis of leptomeningeal metastases in cancer.
    Wang Y; Luo N; Gao Y; Wu Y; Qin X; Qi Y; Sun T; Tao R; Qi C; Liu B; Yuan S
    J Cancer Res Clin Oncol; 2023 May; 149(5):1679-1690. PubMed ID: 35583828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osimertinib Quantitative and Gene Variation Analyses in Cerebrospinal Fluid and Plasma of a Non-small Cell Lung Cancer Patient with Leptomeningeal Metastases.
    Song Y; Liu P; Huang Y; Guan Y; Han X; Shi Y
    Curr Cancer Drug Targets; 2019; 19(8):666-673. PubMed ID: 30332963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid circulating tumor DNA contributes to the detection and characterization of leptomeningeal metastasis in non-small cell lung cancer.
    Miao Q; Zheng X; Li L; Zheng X; Zhang L; Jiang K; Wu S; Wang H; Wu B; Xu Y; Zhong Q; Zou Z; Zhang Q; Yang S; Li Y; Lin G
    J Neurooncol; 2023 Dec; 165(3):517-525. PubMed ID: 38104049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic alterations of cerebrospinal fluid cell-free DNA in leptomeningeal metastases of gastric cancer.
    Chen X; Bai K; Zhang Y; Xu Y; Huo Y; Wang S; Zou Y; Qi X; Guo R; Ou Q; Liu D; Yin S; Chen S; Bu H
    J Transl Med; 2023 May; 21(1):296. PubMed ID: 37131253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of different platforms in detecting EGFR mutations using cerebrospinal fluid cell-free DNA from non-small-cell lung cancer patients with leptomeningeal metastases.
    Chiang CL; Ho HL; Yeh YC; Lee CC; Huang HC; Shen CI; Luo YH; Chen YM; Chiu CH; Chou TY
    Thorac Cancer; 2023 May; 14(14):1251-1259. PubMed ID: 36977550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognosticators of osimertinib treatment outcomes in patients with EGFR-mutant non-small cell lung cancer and leptomeningeal metastasis.
    Chiang CL; Ho HL; Yeh YC; Lee CC; Huang HC; Shen CI; Luo YH; Chen YM; Chiu CH; Chou TY
    J Cancer Res Clin Oncol; 2023 Jan; 149(1):5-14. PubMed ID: 36318332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical Value of Cerebrospinal Fluid ctDNA in Patients 
with Non-small Cell Lung Cancer Meningeal Metastasis].
    Zhang K; Dai Z; Liu S; Li D; Yang D; Cui S
    Zhongguo Fei Ai Za Zhi; 2020 Dec; 23(12):1039-1048. PubMed ID: 33357310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of circulating tumor DNA from non-small cell lung cancer brain metastasis in cerebrospinal fluid samples.
    Ma C; Yang X; Xing W; Yu H; Si T; Guo Z
    Thorac Cancer; 2020 Mar; 11(3):588-593. PubMed ID: 31944608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular characteristics and prognostic factors of leptomeningeal metastasis in non-small cell lung cancer.
    Liu X; Li G; Zhang H; Chang Q; Fang M; Lu C; Tian P; Mei F
    Clin Neurol Neurosurg; 2023 Feb; 225():107572. PubMed ID: 36610238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unique genomic profiles obtained from cerebrospinal fluid cell-free DNA of non-small cell lung cancer patients with leptomeningeal metastases.
    Ying S; Ke H; Ding Y; Liu Y; Tang X; Yang D; Li M; Liu J; Yu B; Xiang J; Mao X; Han-Zhang H; Hu W; Chen L
    Cancer Biol Ther; 2019; 20(4):562-570. PubMed ID: 30395779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid circulating tumor DNA depicts profiling of brain metastasis in NSCLC.
    Wu J; Liu Z; Huang T; Wang Y; Song MM; Song T; Long G; Zhang X; Li X; Zhang L
    Mol Oncol; 2023 May; 17(5):810-824. PubMed ID: 36495130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal Fluid Cell-Free DNA-Based Detection of High Level of Genomic Instability Is Associated With Poor Prognosis in NSCLC Patients With Leptomeningeal Metastases.
    Wu X; Xing P; Shi M; Guo W; Zhao F; Zhu H; Xiao J; Wan J; Li J
    Front Oncol; 2022; 12():664420. PubMed ID: 35574310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing CSF ctDNA to Improve Diagnostic Accuracy and Therapeutic Monitoring in Breast Cancer Leptomeningeal Metastasis.
    Fitzpatrick A; Iravani M; Mills A; Childs L; Alaguthurai T; Clifford A; Garcia-Murillas I; Van Laere S; Dirix L; Harries M; Okines A; Turner NC; Haider S; Tutt ANJ; Isacke CM
    Clin Cancer Res; 2022 Mar; 28(6):1180-1191. PubMed ID: 34921020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liquid biopsy in the setting of leptomeningeal metastases: a systematic review and meta-analysis.
    Wijaya JH; Patel UD; Quintero-Consuegra MD; Aguilera-Peña MP; Madriñán-Navia HJ; Putra AW; July J; Kataria S
    J Neurooncol; 2023 Dec; 165(3):431-438. PubMed ID: 38019327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the cerebrospinal fluid ctDNA detection by next-generation sequencing in the diagnosis of meningeal Carcinomatosis.
    Zhao Y; He JY; Zou YL; Guo XS; Cui JZ; Guo L; Bu H
    BMC Neurol; 2019 Dec; 19(1):331. PubMed ID: 31856745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.